Sign in
Safety and Efficacy of Risuteganib in Intermediate Nonexudative AMD: First Time Results From a Phase 2 Study
Peter K. Kaiser, MD FASRS
Annual Meeting Talks
2019
Gene Expression Profile and Local Tumor Recurrence of Irradiated Uveal Melanomas
Basil K Williams, MD
Updates from the Field
2022
A Comparison of the Anatomical Efficacy of Brolucizumab Versus Aflibercept in nAMD Patients: Matched 16-Week Results From the HAWK and HARRIER Studies
Pravin U. Dugel, MD
2018
Category: AMD-Neovascular